首页> 外国专利> Immunostimulant, carcinostatics TF-2 by cultivation of fusobacterium - esp. F. nucleatum, under anaerobic conditions, pptn. of supernatant with hydrophilic solvent and fractionation by Ph and protein removal

Immunostimulant, carcinostatics TF-2 by cultivation of fusobacterium - esp. F. nucleatum, under anaerobic conditions, pptn. of supernatant with hydrophilic solvent and fractionation by Ph and protein removal

机译:免疫刺激剂,抑菌剂TF-2,通过培养梭菌-尤其是。 F. nucleatum,在厌氧条件下,pptn。亲水溶剂分离上清液并通过Ph和蛋白质去除分离

摘要

Prodn. of carcinostatic substances, TF-2, comprises cultivation of TF-2 producing bacterial strains of the Fusobacterium family and recovery of TF-2 from the culture or from the supernatant liq. New substances described are designated TF-210, 220, 230, 240, 300 (310,320,330) 340 and 350. Used as carcinostatic cpds. and immuno stimulants which may be administered orally, rectally or parenterally, pref. by injection in daily of 0.005-50 mg/kg for adults. Activity tests against Ehrlich ascitic tumours, Sarcoma 180, Ehrlich solid tumour and melanoma B-16 are described. The cpds. are particularly effective against solid tumours. Toxicity tests in mice gave intravenous LD50 values of above 200 mg/kg for TF-220, 240, 250, 340 and 350, above 100 mg/kg for TF-210 and 230 and above 10 mg/kg for TF-300.
机译:产品抑癌物质TF-2的制备包括培养产Fusobacter家族的TF-2的细菌菌株,并从培养物或上清液中回收TF-2。所描述的新物质标记为TF-210、220、230、240、300(310,320,330)340和350。用作抑癌药。以及可以口服,直肠或肠胃外给药的免疫刺激剂。成人每天注射0.005-50 mg / kg。描述了针对艾氏腹水,肉瘤180,艾氏实体瘤和黑色素瘤B-16的活性测试。 cpds。对实体瘤特别有效。小鼠的毒性试验得出TF-220、240、250、250、340和350的静脉LD50值大于200 mg / kg,TF-210和230的静脉内LD50值大于100 mg / kg,TF-300的静脉LD50值大于10 mg / kg。

著录项

  • 公开/公告号ES8308926A1

    专利类型

  • 公开/公告日1983-10-01

    原文格式PDF

  • 申请/专利权人 TOYAMA CHEMICAL CO. LTD.;

    申请/专利号ES19820509774

  • 发明设计人

    申请日1982-02-19

  • 分类号C12P1/04;A61K45/05;

  • 国家 ES

  • 入库时间 2022-08-22 10:43:56

相似文献

  • 专利
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号